Precision BioSciences' PBGENE-HBV Shows Durable RNA Loss in Hepatitis B Trial
Event summary
- Precision BioSciences selected for late-breaking oral presentation at AASLD The Liver Meeting 2026 on November 8.
- PBGENE-HBV trial shows durable pgRNA loss in both HBeAg positive and negative patients.
- ELIMINATE-B Phase 1 trial enrolling globally with goal of defining optimal dose for cccDNA elimination.
- FDA has granted Fast Track designation to PBGENE-HBV.
The big picture
Precision BioSciences' presentation at AASLD highlights the potential of its ARCUS platform in achieving a functional cure for chronic hepatitis B, a condition with significant unmet medical need. The durable pgRNA loss data positions PBGENE-HBV as a leading candidate in the gene editing space, with implications for both Precision's market valuation and the broader adoption of in vivo gene editing therapies. The global enrollment in the ELIMINATE-B trial underscores the clinical and commercial significance of this development.
What we're watching
- Clinical Efficacy
- Whether durable pgRNA loss translates to sustained viral cure in chronic hepatitis B patients.
- Regulatory Pathway
- The pace at which FDA Fast Track designation accelerates PBGENE-HBV's approval process.
- Market Positioning
- How Precision BioSciences differentiates ARCUS platform in the competitive gene editing space.
Related topics
